Frontlight ResearchEarly access
CompletedNo phase
Attexis and tDCS for the Treatment of ADHD
Key facts
- Who runs it
- University of Regensburg
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 1 Sept 2024
- Ended
- 24 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- transcranial direct current stimulation
- sham transcranial direct current stimulation
- Record updated
- 27 February 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Gender: female, male, non-binary
- Age: 18 - 65
- Diagnosis of ADHD according to ICD-10
- ADHD severity score (cut-off): Score of ≥17 on either the inattention subscale or the impulsivity/hyperactivity subscale of the ASRS v1.1
- Stable treatment (psychotherapy, medication, no treatment, ...) (if applicable) for at least 30 days at the time of admission
- Consent to participate
- Sufficient knowledge of the German language
Who cannot take part
- Plan to change an ongoing treatment (psychotherapy, medication, ...) in the next three months after enrollment in the study
- Fulfillment of the contraindications for tDCS (electrical implants or metallic objects in the body such as pacemakers or insulin pumps, skin diseases on the head)
- Neurological diseases (e.g. cerebrovascular events, neurodegenerative diseases, epilepsy, brain malformation, history of severe head injuries)
- Diagnosis of a comorbid clinically relevant severe psychiatric disorder (severe affective disorder, autism spectrum disorder, psychotic disorder, borderline personality disorder, antisocial personality disorder, substance use disorder, suicidality)
- tDCS:
- Participation in another study during treatment
- Pregnancy or breastfeeding; Attexis:
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A randomized controlled two-arm study (RCT) will be conducted. It is planned to randomly assign eligible patients who receive a three-month access to the psychotherapeutic program (Attexis) to either an additional verum-tDCS or placebo-tDCS condition.
The 2 groups in the trial
- Attexis and tDCSTreatment being tested
15 patients receive three-month access to the psychotherapy app attexis and a tDCS device from the company Sooma, which is set to verum
Treatment: transcranial direct current stimulation
- Attexis and placebo-tDCSPlacebo, for comparison
15 patients receive three-month access to the psychotherapy app attexis and a tDCS device from the company Sooma, which is set to sham
Treatment: sham transcranial direct current stimulation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Augmentation Von Online-Psychotherapie Mit tDCS Bei Der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS)
- Record updated
- 27 February 2026